Depleting Tumor Cells Expressing Immune Checkpoint Ligands—A New Approach to Combat Cancer
Antibodies against inhibitory immune checkpoint molecules (ICPMs), referred to as immune checkpoint inhibitors (ICIs), have gained a prominent place in cancer therapy. Several ICIs in clinical use have been engineered to be devoid of effector functions because of the fear that ICIs with preserved ef...
Збережено в:
| Автори: | , |
|---|---|
| Формат: | Artigo |
| Мова: | Inglês |
| Опубліковано: |
MDPI AG
2021-04-01
|
| Серія: | Cells |
| Предмети: | |
| Онлайн доступ: | https://www.mdpi.com/2073-4409/10/4/872 |
| Теги: |
Немає тегів, Будьте першим, хто поставить тег для цього запису!
|